Physician profile
Ashesh Modi
NPI 1174674816
$2,631.30
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $31.92 · 2021: $155 · 2022: $284 · 2023: $397 · 2024: $818 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.14 | 2021-2025 | |
| Madrigal Pharmaceuticals | $184.73 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $184.39 | 2019-2025 | |
| Janssen Biotech, INC. | $171.73 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.44 | 2023-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $142.99 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $141.73 | 2020-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $120.00 | 2024 | |
| Genzyme Corporation | $118.42 | 2025 | |
| Ardelyx, INC. | $102.03 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $95.38 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $83.55 | 2019-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $70.37 | 2023 | Dificid |
| Lilly USA, LLC | $48.19 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $47.41 | 2024-2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.49 | 2021-2025 | Injectafer |
| Gilead Sciences, INC. | $42.93 | 2022-2025 | |
| Micro-Tech Endoscopy USA, INC. | $40.33 | 2024-2025 | Blueboost |
| Ferring Pharmaceuticals INC. | $33.21 | 2023 | Rebyota |
| Olympus America INC. | $29.18 | 2019 | |
| Novo Nordisk INC | $23.60 | 2025 | Wegovy |
| Shionogi INC | $17.08 | 2019 | |
| Sandoz INC. | $16.68 | 2024 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $16.64 | 2022 | |
| Medtronic, INC. | $14.66 | 2023 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashesh Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.